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Schizophrenia is frequently associated with abnormal motor behavior, particularly hypoki-
nesia. The course of the illness tends to deteriorate in the first years. We aimed to assess
gross motor activity in patients with a first episode (n=33) and multiple episodes (n=115)
of schizophrenia spectrum disorders using wrist actigraphy. First episode patients were
younger, had higher motor activity and reduced negative symptom severity. Covarying
for age, chlorpromazine equivalents, and negative symptoms, first episode patients still
had higher motor activity. This was also true after excluding patients with schizophreni-
form disorder from the analyses. In first episode patients, but not in patients with multiple
episodes, motor activity was correlated with antipsychotic dosage. In conclusion, after
controlling for variables related to disorder chronicity, patients with first episodes were still
more active than patients with multiple episodes.Thus, reduced motor activity is a marker
of deterioration in the course of schizophrenia spectrum disorders.
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INTRODUCTION
The first episode is of particular interest to schizophrenia research
because it allows assessing the clinical presentation in the absence
of factors related to illness chronicity. Longitudinal studies have
demonstrated a strong decline in function and quality of life dur-
ing the first 2–5 years. Despite vast heterogeneity in illness course,
the condition during initial episode has some predictive value (1).
Motor abnormalities are intrinsic to schizophrenia and have
been reported throughout the whole course of the disorder irre-
spective of medication status (2–6). Particularly, psychomotor
slowing impacts cognitive performance and outcome (7). Objec-
tive measures acquired with actigraphy have established hypoki-
nesia in schizophrenia, which is correlated with negative symptom
severity (8–10). However, objectively assessed gross motor activity
has not been tested in first episode patients. Even though 67% of
unmedicated first episode patients present with at least one motor
sign (11), first episode patients tend to present with less or compa-
rably severe negative symptoms as patients with multiple episodes
(12, 13). Thus, the current study aimed to test whether physical
activity as measured by wrist actigraphy would differ between first
episode and multiple episode patients with schizophrenia spec-
trum disorders. Furthermore, we aimed to explore the association
of physical activity with antipsychotic dosage and negative syn-
drome severity in both groups. We hypothesized that physical
activity was higher in first episode patients compared to multi-
ple episode patients, as functional decline often occurs within the
early course of the disorder (1).
MATERIALS AND METHODS
PATIENTS
To explore differences between patients with a first vs. multiple
episodes on physical activity, we pooled data from previous and
ongoing studies applying actigraphy in schizophrenia spectrum
disorders (9, 14–19). A total of 148 patients with schizophrenia
spectrum disorders were included (first episode n= 33, multiple
episodes n= 115). The patients with multiple episodes had on
average 7.9 episodes (SD= 6.2). Diagnoses were given according
to DSM-IV criteria after thorough clinical examination and review
of all case files by board certified psychiatrists. The local mental
health care system ensures that most of the patients are admitted
to our clinic in every psychotic episode requiring inpatient treat-
ment, allowing the collection of reliable diagnostic information.
In a proportion of studies that contributed data to this analysis,
the diagnoses were ascertained by structured clinical interviews
such as SCID and MINI (27% of cases). Diagnoses given included
paranoid schizophrenia (33% of first episode vs. 55% of multiple
episode patients), catatonic schizophrenia (12 vs. 11%), disorga-
nized schizophrenia (0 vs. 16%), schizoaffective disorder (6 vs.
5%), and schizophreniform disorder (49 vs. 13%) with significant
differences between groups (χ2= 21.7, df= 1, p< 0.001). Patients
were excluded in case of substance abuse other than nicotine,
medical conditions affecting physical activity, and epilepsy. Phys-
ical activity was recorded approximately 2 weeks after admission
to the psychiatric department. At the same time, psychopathol-
ogy was assessed using the positive and negative syndrome scale
(PANSS) (20). Most patients were medicated (71% received atyp-
ical antipsychotics, 18% received mixed medication of typical and
atypical antipsychotics, 6% received only typical antipsychotics,
and 5% were medication-free at the time of our assessments).
Chlorpromazine equivalents (CPZ) of the current antipsychotic
pharmacotherapy were calculated according to Woods (21). In
addition, diazepam equivalents (DE) were calculated according to
Ashton (22). The protocols of the studies applying wrist actig-
raphy in schizophrenia spectrum disorders had been approved
by the local ethics committee and participants provided written
informed consent prior to study inclusion.
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ACTIGRAPHY
Participants wore an actigraph (Actiwatch, Cambridge Neurotech-
nology, Inc., Cambridge, UK) for 24 consecutive hours at the wrist
of the non-dominant arm. The piezoelectric sensor converts accel-
eration into movement counts. Data were sampled in 2 s intervals.
Participants provided sleep log information and information on
recording pauses (due to showering or bathing). Only the data
collected during wakeful periods of the 24 h recording time were
analyzed. Activity counts were averaged to provide the activity level
(AL) in counts/h.
STATISTICAL ANALYSES
Demographic and clinical parameters were compared between
groups by one-way ANOVAs and χ2-tests. Since groups differed
in the PANSS negative syndrome subscale score, age, and CPZ
dosage, these variables were entered as covariates in an ANCOVA
of AL. Furthermore, as the group of first episode patients included
a large proportion of patients with schizophreniform disorder,
we recalculated the ANCOVA excluding all patients with schizo-
phreniform disorder. In order to test the additional effects of illness
duration and benzodiazepine administration, we recalculated the
ANCOVA first including duration of illness, negative symptoms,
and CPZ as covariate and second including duration of illness,
negative symptoms, CPZ, and DE as covariates. Furthermore, we
compared AL in patients with different medication types (typical
antipsychotics, atypical antipsychotics, and mixed medication).
Next, clinical and demographic variables were correlated with AL
for both groups separately. Because of the divergent results, we
also calculated the interaction of CPZ and group on AL using
an ANCOVA in the whole sample. Besides the classical PANSS
subscores, we also tested the five PANSS factors according to van
der Gaag and colleagues (23) (positive, negative, disorganization,
excitement, and emotional distress), and the avolition score (sum
of items N2+N4) according to Bervoets et al. (24). All tests were
performed with SPSS 21.
RESULTS
Gender distribution was not different between groups (first
episode patients 61% male, multiple episode patients 57% male,
χ2= 0.175, df= 1, p= 0.696).
First episode patients had increased AL, were younger, received
lower doses of antipsychotics and had a trend to reduced PANSS
negative scores (see Table 1). Furthermore, first episode patients
had reduced scores in the PANSS factors negative, disorganization,
and excitement (23), as well as the PANSS avolition score (24).
The difference in AL between groups remained when adding the
PANSS negative syndrome subscale score, age, and CPZ as covari-
ates (F = 6.2, df= 4, p< 0.001,η2=0.15). Furthermore, including
duration of illness, negative symptoms, and CPZ as covariate
did not substantially alter the results (F = 4.53; df= 4; p= 0.002;
η= 0.12). Moreover, differences in AL between groups remained
stable with the inclusion of duration of illness, negative symptoms,
CPZ, and DE as covariates (F = 4.23; df= 5; p= 0.001; η= 0.13).
Likewise, the difference in AL between groups remained when all
subjects with schizophreniform disorder were excluded from the
ANCOVA (F = 4.2, df= 4, p= 0.003, η2= 0.13) with the PANSS
negative syndrome subscale score, age, and CPZ as covariates.










Activity level (counts/h) 18057 (9194) 13551 (7047) 9.7 0.002
Age (years) 31.9 (12.5) 39.6 (11.2) 15.4 <0.001
Duration of
illness (years)
1.7 (3.2) 12.7 (10.2) 30.9 <0.001
CPZ (mg) 360.2 (341.2) 530.5 (399.9) 3.9 0.049
DE (mg) 6.3 (10.5) 5.0 (10.1) 0.6 0.547
PANSS positive
subscale
13.4 (4.6) 15.7 (5.6) 1.5 0.226
PANSS negative
subscale
15.9 (6.5) 18.1 (6.2) 3.2 0.078
PANSS total score 61.1 (15.8) 68.7 (16.2) 5.5 0.020
PANSS avolition 4.0 (2.2) 5.0 (2.2) 5.3 0.022
PANSS factor positive 16.1 (7.1) 17.7 (6.6) 1.4 0.239
PANSS factor negative 15.2 (7.8) 18.3 (7.0) 4.6 0.033
PANSS factor
disorganization
20.9 (5.7) 24.2 (6.6) 6.6 0.011
PANSS factor
excitement
13.2 (3.9) 15.4 (5.3) 5.1 0.026
PANSS factor emotional
distress
14.7 (6.1) 16.0 (5.5) 1.4 0.242
Numbers are given as mean (SD).
Finally, AL did not differ between groups with distinct antipsy-
chotic medication (typical, atypical antipsychotics, and mixed
medication) (F = 0.96; df= 2; p= 0.386; η= 0.01).
Correlations between AL and clinical parameters are given in
Table 2. Associations with measures of the negative syndrome were
more dominant in the patients with multiple episodes. Groups
differed in the correlation of CPZ and AL, with significant effects
in first episode patients and no effects in patients with multiple
episodes (ANCOVA of AL with intercept between CPZ and group
F = 11.3, df= 1, p< 0.001, η2= 0.07).
DISCUSSION
In the present study, we were able to demonstrate that patients in
a first episode of schizophrenia spectrum disorders have higher
physical activity than patients with multiple episodes. This result
held true after controlling for negative symptoms, age, dosage of
antipsychotics, and administration of benzodiazepines. Further-
more, it was still evident after excluding patients with schizo-
phreniform disorder. Thus, we are confident that there is a true
difference in physical activity between the groups beyond other
major differences that are related to illness duration. Of course,
the magnitude of the effect was small to medium in size as there
are also other factors contributing to physical activity besides age,
chronicity, and negative symptoms, such as lifestyle habits and
physical constitution. Still, the mean AL value of the first episode
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r p r p
Age −0.21 0.251 −0.19 0.038
CPZ −0.46 0.008 0.08 0.411
DE −0.03 0.893 −0.29 0.002
PANSS positive syndrome score 0.07 0.698 0.13 0.163
PANSS negative syndrome score −0.02 0.910 −0.29 0.001
PANSS total score −0.07 0.708 −0.17 0.070
PANSS avolition factor −0.38 0.031 −0.29 0.002
PANSS positive factor −0.05 0.784 −0.01 0.897
PANSS negative factor −0.33 0.064 −0.32 <0.001
PANSS disorganization factor 0.32 0.073 −0.08 0.399
PANSS excitement factor −0.04 0.835 −0.08 0.418
PANSS emotional distress factor −0.05 0.800 −0.13 0.183
patients is close to the mean of AL reported in different samples
of healthy controls, e.g., 18000–21000 counts/h (8, 15, 25). Fur-
thermore, subjects at ultra high risk for psychosis were shown to
have reduced ALs at trend level compared to matched controls
(26). Thus, even though the AL of first episode patients might
still be slightly reduced compared to age matched controls, AL
appear comparable to those of healthy control groups with wider
age ranges. Our finding is in line with the observation that motor
abnormalities are present from the first episode of schizophrenia
spectrum disorders but tend to deteriorate with the progression
of the disorder (2, 5). Likewise, neurocognitive measures of fine
motor performance have indicated impairments in first episode
patients and even more in chronic patients (27). However, it
remains unknown, which factors drive the reduction of physical
activity in patients with multiple episodes. Clearly, negative symp-
toms are related to reduced physical activity (8–10). In addition,
the use of catatonia rating scales such as the modified Rogers scale
(28) indicated that the frequency of the item “marked underactiv-
ity” was increased in a mixed sample of schizophrenia spectrum
disorder patients as compared to first episode patients (28 vs. 9%)
(11, 29). In general, motor abnormalities are prevalent in the early
course but increase in frequency with multiple episodes. In many
instances, it is hard to disentangle the multiple causes of hypoki-
nesia, such as catatonia, parkinsonism, or reduced volition, i.e.,
negative symptoms (2). If reduction of physical activity was an
indicator of deterioration, it would well fit in the observation of
clinical deterioration within the first 2–5 years after the onset of
schizophrenia spectrum disorders (1). First evidence suggests that
hypokinesia due to parkinsonism in first episode patients was pre-
dictive of poor cognitive function after 6 months (30). However,
schizophrenia presents with a heterogeneous longitudinal course
and deterioration of symptoms is not everyone’s fate (31).
Another important finding of the present study is the inter-
action of antipsychotic dosage and group on AL. Whereas, in
multiple episode patients, we were unable to find a correlation
of AL and CPZ, increased antipsychotic dosage was related to
lower AL in first episode patients. Here, we may speculate that
in first episode patients in the absence of marked negative symp-
toms, parkinsonism, or catatonia, antipsychotic agents may exert
more impact on the overall motor activity. However, this view is
partly challenged by the fact that antipsychotic agents ameliorate
most psychomotor impairments in previously naïve first episode
patients, including hypokinesia, parkinsonism, and catatonia (11).
Still, the various antipsychotic agents currently used may exert
differential effects on physical activity or spontaneous, i.e., preex-
isting motor symptoms. So far, only few reports exist investigating
the effect of different antipsychotic agents on motor behavior in
previously unmedicated subjects (32). However, we found no dif-
ferences of AL in patients with different medication types (typical,
atypical antipsychotics, and mixed medication).
In line with previous reports, reduced motor activity was asso-
ciated with negative symptoms in both first episode and chronic
schizophrenia spectrum disorders (8, 9). Also, reduced tongue
movements were demonstrated to correlate with negative symp-
toms in first episode patients (33). Likewise, hypokinesia was
associated with negative symptoms in first episode patients (11).
In chronic schizophrenia, various measures of hypokinesia have
demonstrated correlations with negative symptom severity, par-
ticularly the initiation of movements seems affected (2, 24, 29, 34,
35). As in one previous report, the avolition component of the
negative syndrome displayed strongest correlations with sponta-
neous motor activity (8). Thus, our data support the assumption
that actigraphy may particularly well suited to assess motivational
aspects of the negative syndrome. Finally, exercise interventions
have regained interest in schizophrenia targeting various problems
of these patients, such as metabolic, cognitive, and social problems
(36). First controlled studies reported positive effects of exer-
cise interventions on negative symptoms and working memory
in schizophrenia (37).
This study has some limitations requiring discussion. We have
used data from a database to answer the research question. The
methods of actigraphy and PANSS assessment were the com-
mon ground. If we had to conduct a new study on this topic,
we would include more standardized measures of motor function
focusing on parkinsonism and catatonia. Parkinsonism and cata-
tonia may have influenced AL (2, 38). However, both symptoms
are frequently present in patients with a first psychotic episode
and in patients with multiple episodes (11). Still, these symptoms
might be more frequent in patients with a chronic course of the
disease (14). However, treatment with antipsychotics shows a het-
erogeneous effect on parkinsonism and catatonia in previously
antipsychotic naïve patients: in some patients, these symptoms
are ameliorated by treatment, in others they tend to emerge or
deteriorate during pharmacotherapy, while in a third group symp-
toms remain unchanged with antipsychotic medication (32). In
addition, there are better scales to assess negative symptoms (39).
Still, the PANSS is a commonly used instrument, which aids data
interpretation. Finally, we did not measure depressive symptoms,
even though, depression might affect ALs. Patients with major
depression move less than healthy controls (40). Still, in a pre-
vious investigation, we found only weak associations in major
depressed patients between depression severity as assessed by the
Hamilton depression rating scale (HAMD) and AL (41). However,
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taking the emotional dysregulation factor according to van der
Gaag (23) as a substitute parameter for depression, we failed to
identify correlations with AL in any of the two groups.
In conclusion, we demonstrated that first episode patients have
higher physical activity than patients with multiple episodes. The
finding underlines that functional deterioration including reduced
motor activity frequently occurs beyond the first episode. Thus,
future studies should evaluate whether this reduction may be tar-
geted by pharmacotherapy or specialized programs to promote
physical exercise in schizophrenia (36, 42).
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